LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 350

Search options

  1. Book: Themed special issue on: mechanisms of BCR-ABL leukemogenesis and novel targets for the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia

    Platanias, Leonidas C.

    (Leukemia & lymphoma ; 52, Suppl. 1)

    2011  

    Title variant Mechanisms of BCR-ABL leukemogenesis and novel targets for the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia ; Themed special issue on: mechanisms of BCR-ABL leukemogenesis and novel targets for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia
    Author's details guest ed.: Leonidas Platanias
    Series title Leukemia & lymphoma ; 52, Suppl. 1
    Collection
    Language English
    Size 91 S. : Ill., graph. Darst.
    Publisher Informa Healthcare
    Publishing place New York, NY
    Publishing country Switzerland
    Document type Book
    HBZ-ID HT016745271
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Article ; Online: A novel approach to overcome drug resistance in acute myeloid leukemia.

    Mazewski, Candice / Platanias, Leonidas C

    Haematologica

    2023  Volume 108, Issue 11, Page(s) 2889–2890

    MeSH term(s) Humans ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/genetics ; Drug Resistance, Neoplasm/genetics
    Language English
    Publishing date 2023-11-01
    Publishing country Italy
    Document type Editorial ; Comment
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2023.283099
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Book: Cytokines and cancer

    Platanias, Leonidas C.

    (Cancer treatment and research ; 126)

    2005  

    Author's details ed. by Leonidas C. Platanias
    Series title Cancer treatment and research ; 126
    Collection
    Keywords Neoplasms / therapy ; Cytokines / therapeutic use ; Krebs ; Cytokine ; Pharmakotherapie
    Subject Arzneimitteltherapie ; Arzneitherapie ; Medikamentöse Therapie ; Zytokine ; Carcinom ; Malignom ; Maligner Tumor ; Neoplasma ; Karzinom ; Bösartiger Tumor ; Krebserkrankung
    Language English
    Size X, 377 S. : Ill.
    Publisher Springer
    Publishing place New York
    Publishing country United States
    Document type Book
    HBZ-ID HT014355765
    ISBN 0-387-24360-7 ; 978-0-387-24360-3
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  4. Article: MNK Proteins as Therapeutic Targets in Leukemia.

    Mazewski, Candice / Platanias, Leonidas C

    OncoTargets and therapy

    2023  Volume 16, Page(s) 283–295

    Abstract: In leukemia, resistance to therapy is a major concern for survival. MAPK-interacting kinases (MNKs) have been identified as important activators of oncogenic-related signaling and may be mediators of resistance. Recent studies in leukemia models, ... ...

    Abstract In leukemia, resistance to therapy is a major concern for survival. MAPK-interacting kinases (MNKs) have been identified as important activators of oncogenic-related signaling and may be mediators of resistance. Recent studies in leukemia models, especially acute myeloid leukemia (AML), have focused on targeting MNKs together with other inhibitors or treating chemotherapy-resistant cells with MNK inhibitors. The preclinical demonstrations of the efficacy of MNK inhibitors in these combination formats would suggest a promising potential for use in clinical trials. Optimizing MNK inhibitors and testing in leukemia models is actively being pursued and may have important implications for the future. These studies are furthering the understanding of the mechanisms of MNKs in cancer which could translate to clinical studies.
    Language English
    Publishing date 2023-04-21
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2495130-4
    ISSN 1178-6930
    ISSN 1178-6930
    DOI 10.2147/OTT.S370874
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Signaling by Type I Interferons in Immune Cells: Disease Consequences.

    Zannikou, Markella / Fish, Eleanor N / Platanias, Leonidas C

    Cancers

    2024  Volume 16, Issue 8

    Abstract: This review addresses interferon (IFN) signaling in immune cells and the tumor microenvironment (TME) and examines how this affects cancer progression. The data reveal that IFNs exert dual roles in cancers, dependent on the TME, exhibiting both anti- ... ...

    Abstract This review addresses interferon (IFN) signaling in immune cells and the tumor microenvironment (TME) and examines how this affects cancer progression. The data reveal that IFNs exert dual roles in cancers, dependent on the TME, exhibiting both anti-tumor activity and promoting cancer progression. We discuss the abnormal IFN signaling induced by cancerous cells that alters immune responses to permit their survival and proliferation.
    Language English
    Publishing date 2024-04-22
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers16081600
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Emerging Role of Glioma Stem Cells in Mechanisms of Therapy Resistance.

    Eckerdt, Frank / Platanias, Leonidas C

    Cancers

    2023  Volume 15, Issue 13

    Abstract: Since their discovery at the beginning of this millennium, glioma stem cells (GSCs) have sparked extensive research and an energetic scientific debate about their contribution to glioblastoma (GBM) initiation, progression, relapse, and resistance. ... ...

    Abstract Since their discovery at the beginning of this millennium, glioma stem cells (GSCs) have sparked extensive research and an energetic scientific debate about their contribution to glioblastoma (GBM) initiation, progression, relapse, and resistance. Different molecular subtypes of GBM coexist within the same tumor, and they display differential sensitivity to chemotherapy. GSCs contribute to tumor heterogeneity and recapitulate pathway alterations described for the three GBM subtypes found in patients. GSCs show a high degree of plasticity, allowing for interconversion between different molecular GBM subtypes, with distinct proliferative potential, and different degrees of self-renewal and differentiation. This high degree of plasticity permits adaptation to the environmental changes introduced by chemo- and radiation therapy. Evidence from mouse models indicates that GSCs repopulate brain tumors after therapeutic intervention, and due to GSC plasticity, they reconstitute heterogeneity in recurrent tumors. GSCs are also inherently resilient to standard-of-care therapy, and mechanisms of resistance include enhanced DNA damage repair, MGMT promoter demethylation, autophagy, impaired induction of apoptosis, metabolic adaptation, chemoresistance, and immune evasion. The remarkable oncogenic properties of GSCs have inspired considerable interest in better understanding GSC biology and functions, as they might represent attractive targets to advance the currently limited therapeutic options for GBM patients. This has raised expectations for the development of novel targeted therapeutic approaches, including targeting GSC plasticity, chimeric antigen receptor T (CAR T) cells, and oncolytic viruses. In this review, we focus on the role of GSCs as drivers of GBM and therapy resistance, and we discuss how insights into GSC biology and plasticity might advance GSC-directed curative approaches.
    Language English
    Publishing date 2023-07-01
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15133458
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Book ; Online: Cytokines and Cancer

    Platanias, Leonidas C.

    2005  

    Author's details edited by Leonidas C. Platanias
    Keywords Hematology ; Oncology
    Language English
    Publisher Springer Science+Business Media, Inc
    Publishing place Boston, MA
    Document type Book ; Online
    HBZ-ID TT050386789
    ISBN 978-0-387-24360-3 ; 978-0-387-24361-0 ; 0-387-24360-7 ; 0-387-24361-5
    DOI 10.1007/b105234
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  8. Article: Targeting Cytokines and Their Pathways for the Treatment of Cancer.

    Heimberger, Amy B / Tripathi, Shashwat / Platanias, Leonidas C

    Cancers

    2023  Volume 15, Issue 21

    Abstract: This Special Issue focuses on the evolving role of immune modulatory cytokines, from their initial use as monotherapeutic recombinant proteins to their more contemporaneous use as modifiers for adoptive cellular immunotherapy [ ... ]. ...

    Abstract This Special Issue focuses on the evolving role of immune modulatory cytokines, from their initial use as monotherapeutic recombinant proteins to their more contemporaneous use as modifiers for adoptive cellular immunotherapy [...].
    Language English
    Publishing date 2023-10-30
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15215224
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Interferon and myeloproliferative neoplasms: Evolving therapeutic approaches.

    Swaroop, Alok / Saleiro, Diana / Platanias, Leonidas C

    BioEssays : news and reviews in molecular, cellular and developmental biology

    2023  Volume 45, Issue 3, Page(s) e2200203

    Abstract: Interferons (IFNs) are a diverse group of cytokines whose potent antitumor effects have piqued the interest of scientists for decades. Some of the most sustained clinical accomplishments have been in the field of myeloproliferative neoplasms (MPNs). Here, ...

    Abstract Interferons (IFNs) are a diverse group of cytokines whose potent antitumor effects have piqued the interest of scientists for decades. Some of the most sustained clinical accomplishments have been in the field of myeloproliferative neoplasms (MPNs). Here, we discuss how both historical and novel breakthroughs in our understanding of IFN function may lead to more effective therapies for MPNs. The particular relevance and importance of modulating the novel IFN-regulated ULK1 pathway to optimize IFN responses is highlighted.
    MeSH term(s) Humans ; Interferons/therapeutic use ; Myeloproliferative Disorders/drug therapy ; Myeloproliferative Disorders/pathology ; Hematologic Neoplasms/drug therapy
    Chemical Substances Interferons (9008-11-1)
    Language English
    Publishing date 2023-01-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 50140-2
    ISSN 1521-1878 ; 0265-9247
    ISSN (online) 1521-1878
    ISSN 0265-9247
    DOI 10.1002/bies.202200203
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Medicinal chemistry approaches to target the MNK-eIF4E axis in cancer.

    Fernandez, Ann / Monsen, Paige J / Platanias, Leonidas C / Schiltz, Gary E

    RSC medicinal chemistry

    2023  Volume 14, Issue 6, Page(s) 1060–1087

    Abstract: Aberrant translation of proteins that promote cell proliferation is an essential factor that defines oncogenic processes and cancer. The process for ribosomal translation of proteins from mRNA requires an essential initiation step which is controlled by ... ...

    Abstract Aberrant translation of proteins that promote cell proliferation is an essential factor that defines oncogenic processes and cancer. The process for ribosomal translation of proteins from mRNA requires an essential initiation step which is controlled by the protein eIF4E, which binds the RNA 5'-cap and forms the eIF4F complex that subsequently translates protein. Typically, eIF4E is activated by phosphorylation on Ser209 by MNK1 and MNK2 kinases. Substantial work has shown that eIF4E and MNK1/2 are dysregulated in many cancers and this axis has therefore become an active area of interest for developing new cancer therapeutics. This review summarizes and discusses recent work to develop small molecules that target different steps in the MNK-eIF4E axis as potential cancer therapeutics. The aim of this review is to cover the breadth of different molecular approaches being taken and the medicinal chemistry basis for their optimization and testing as new cancer therapeutics.
    Language English
    Publishing date 2023-05-09
    Publishing country England
    Document type Journal Article ; Review
    ISSN 2632-8682
    ISSN (online) 2632-8682
    DOI 10.1039/d3md00121k
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top